13 results on '"E. Zrihen"'
Number of results to display per page
Search Results
2. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials
- Author
-
Mireille Mousseau, Eric Francois, A. Fatisse, A. Bedjaoui, Abakar Mahamat, C. Lombard-Bohas, J. Ezenfis, Marc Porneuf, F. Subtil, M. Tissot, Emilie Maillard, M. Fayolle, J.F. Dor, A. Votte, P. Chiappa, P. Prost, Denis Cléau, P. Bergerault, J.C. Souquet, K. Beerblock, P. Chatrenet, J.M. Sabate, M. Carreiro, S. Beorchia, Vincent Hautefeuille, Jessika Moreau, N. Delas, C. Vilain, Christian Borel, Franck Audemar, M. Duluc, Touraj Mansourbakht, Bernard Denis, Gael Deplanque, Jean-Marc Phelip, C. Brezault, Anne Thirot-Bidault, L. Gasnault, Jean-Louis Jouve, Y. Rinaldi, B. Leduc, Y. Courouble, A. Alessio, Matthieu Schnee, P. Cassan, Antoine Adenis, Jocelyne Provencal, A. Botton, Laurent Cany, Françoise Desseigne, Marie-Christine Kaminsky, Mohamed Ramdani, B. Lafforgue, L. Rob, J.C. Barbare, S. Jacquot, A. Zaanan, J.-Y. Douillard, C. Cornila, B. Rhein, Benjamin Linot, Z. Ladhib, D. Zylberait, Cedric Lecaille, N. Hess-Laurens, H. Brixi-Benmansour, C. Rebischung, C. Giraud, L. Stefani, D. Pillon, J.P. Lafargue, J. Forestier, P. Laplaige, C. Paoletti, S. Lavau Denes, Etienne Suc, A. Patenotte, E. Echinard, François-Xavier Caroli-Bosc, D. Goldfain, V. Quentin, Hervé Perrier, J.D. Grangé, A. Marre, M. Baconnier, Bruno Coudert, Thomas Walter, R. Benoit, A. Blanchi, A.C. Dupont-Gossart, Emilie Barbier, X. Coulaud, D. Besson, Isabelle Trouilloud, D. Sevin-Robiche, M Giovannini, O. Boulat, C. Lobry, H. Castanie, Y. Molin, Thomas Aparicio, Valérie Boige, P. Lehair, J.P. Robin, J.P. Latrive, J. Goineau, Clément Belletier, G. Medinger, C. Lepere, Philippe Rougier, N. Bouaria, E. Carola, V. Derias, Bernard Paillot, Yves Becouarn, F. Kikolski, Martin Combe, Julie Vincent, C. Briac-Levaché, C. Becht, François Ghiringhelli, J. Charneau, Dany Gargot, Julien Vergniol, Denis Péré-Vergé, P. Pienkowski, Patrick Texereau, I. Baumgaertner, J.P. Ramain, Pierre-Luc Etienne, P. Claudé, Jean Francois Paitel, J.P. Plachot, M.-C. Clavero-Fabri, P. Geoffroy, A. Cadier-Lagnes, Y. Le Bricquir, S. Fratte, O. Favre, Aimery de Gramont, J. Butel, David Tougeron, B. Winkfield, E. Janssen, J. Meunier, Julien Volet, N. Gérardin, D. Soubrane, Vincent Bourgeois, Xavier Adhoute, Y.H. Lam, P.A. Haineaux, A. Rotenberg, J-B. Bachet, C. Berger, F. Almaric, J. Tuaillon, G. Gatineau-Saillant, F. Zerouala-Boussaha, E. Cuillerier, R. Lamy, D. Luet, D. Baudet-Klepping, E.A. Pariente, M. Gignoux, J. Martin, M. Blasquez, Romain Coriat, C. Bineau, J. Boutin, A. Aouakli, F. Dewaele, A.M. Queuniet, V. Sebbagh, P. Couzigou, N. Barrière, Faiza Khemissa, P. Follana, Laurence Chone, F. Petit-Laurent, N. Abdelli, Olivier Capitain, D. Bechade, Corinne Sarda, J.P. Herr, P. Pouderoux, Julien Taieb, M. Pauwels, E. Zrihen, L. Wander, Gael Goujon, G. Boilleau-Jolimoy, Anne Thirot Bidault, B. Landi, V. Jestin Le Tallec, Jaafar Bennouna, O. Berthelet, M. Glikmanas, H. Salloum, Côme Lepage, Thierry Lecomte, P. Amoyal, C. Platini, Veronique Guerin-Meyer, B. Garcia, Laetitia Dahan, Pascal Burtin, J. Villand, S. Nguyen, A. Roussel, F. Di Fiore, S. Oddou-Lagraniere, J.P. Aucouturier, Veronique Lorgis, Gerard Cavaglione, J.P. Lagasse, Dominique Auby, Pierre Michel, F. Bonnetain, Gilles Breysacher, R. Mackiewicz, Philippe Ruszniewski, T. Morin, J. Thaury, Clara Locher, J.M. Vantelon, S. Nasca, J.P. Barbieux, H. Maechel, Y. Coscas, May Mabro, S. Montembault, P. Novello, M. Charbit, J. Deguiral, A. Gagnaire, D. Festin, A. Gueye, Hélène Senellart, Achim Weber, Nadia Bouarioua, Jérôme Dauba, Michel Ducreux, Jean-Luc Raoul, G. Coulanjon, J.N. Vaillant, S. Chaussade, A. Gilbert, Anne-Laure Villing, Dominique Genet, P. Martin, M. Ben Abdelghani, M.P. Galais, A. Azzedine, A. Lemaire, C. Barberis, C. Buffet, J. Egreteau, G. Roquin, M. Mornet, Isabelle Cumin, M. Pelletier, P. Feydy, J. Lacourt, T. Chatellier, Jean-Louis Legoux, M. Benchalal, I. Graber, S. Nahon, P. Pantioni, A. Hollebecque, M. Zawadi, Pascal Hammel, M. Mignot, Roger Faroux, J. Lafon, Mohamed Gasmi, Jean-Philippe Spano, S. Pesque-Penaud, C. de la Fouchardiere, J. Cretin, Olivier Bouché, D. Smith, E. Norguet-Monnereau, G. Bordes, Sylvain Manfredi, Thévenet P, Herve Lacroix, E. Dorval Danquechin, Eric Terrebonne, Laurent Bedenne, P. Godeau, David Malka, V. Veuillez, Emmanuel Mitry, F. Riot, Sandrine Hiret, François Morvan, M.C. Gouttebel, Jean-François Seitz, Karine Bouhier-Leporrier, N. Stremsdoerfer, P. Souillac, M. Mozer, C. Couffon, F. Husseini, J.M. Cheula, J.-M. Gornet, K. Slimane Fawzi, Service d'hépato-gastro-entérologie [Hôpital Saint-Louis], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Sorbonne Paris Cité (USPC), Université Paris-Saclay, Oncologie digestive, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Service de gastroentérologie (CHD Vendee - Hopital Les Oudairies, La Roche Sur Yon), CHD Vendee (La Roche Sur Yon), Fédération Francophone de la Cancérologie Digestive, FFCD, Lipides - Nutrition - Cancer [Dijon - U1231] (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Université Bourgogne Franche-Comté [COMUE] (UBFC), Service d'Hépato-Gastro-Entérologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Département d'hépato-gastro-entérologie [Hôpital Trousseau : CHRU Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Privé des Côtes d'Armor (HPCA), Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER, Service de gastroentérologie [CHU Saint-Etienne], Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Institut de Cancérologie de la Loire [Saint-Priest en Jarez], Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA), Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen]-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU), Service d'hépato-gastro-entérologie et oncologie digestive [CHR Orléans], Centre Hospitalier Régional d'Orléans (CHRO), Service De Gastroenterologie, Hôpital Nord, Assistance Publique-Hôpitaux de Marseille, Hôpital Louis Pasteur [Colmar] (CH Colmar), Département d'hépato-gastro-entérologie [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes)-Institut des Maladies de l’Appareil Digestif [CHU Nantes], Service d'oncologie [Institut Hospitalier Franco-Britannique : Levallois-Perret], Institut hospitalier Franco-Britannique [Levallois-Perret], Département d'oncologie médicale (CHU Robert Debré, Reims), Centre Hospitalier Universitaire de Reims (CHU Reims), Service d'oncologie digestive et hépato-gastro-entérologie [Hôpital de la Timone - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-CHU Trousseau [APHP], Hôpital Charles Nicolle [Rouen]-CHU Rouen, and Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN)
- Subjects
Male ,0301 basic medicine ,Cancer Research ,medicine.medical_specialty ,Bevacizumab ,Colorectal cancer ,Angiogenesis Inhibitors ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Kaplan-Meier Estimate ,Overweight ,Gastroenterology ,Pooled analysis ,Body Mass Index ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Outcome Assessment, Health Care ,Individual data ,medicine ,Overall survival ,Humans ,Neoplasm Metastasis ,Objective response ,Aged ,2. Zero hunger ,Clinical Trials as Topic ,Prognostic factor ,business.industry ,nutritional and metabolic diseases ,[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology ,Prognosis ,medicine.disease ,3. Good health ,030104 developmental biology ,Oncology ,Normal weight ,030220 oncology & carcinogenesis ,Female ,medicine.symptom ,Colorectal Neoplasms ,business ,medicine.drug - Abstract
IF 7.191 (2017); International audience; BACKGROUND:Previous studies showed that high and low body mass index (BMI) was associated with worse prognosis in early-stage colorectal cancer (CRC), and low BMI was associated with worse prognosis in metastatic CRC (mCRC). We aimed to assess efficacy outcomes according to BMI.PATIENTS AND METHODS:A pooled analysis of individual data from 2085 patients enrolled in eight FFCD first-line mCRC trials from 1991 to 2013 was performed. Comparisons were made according to the BMI cut-off: Obese (BMI ≥30), overweight patients (BMI ≥ 25), normal BMI patients (BMI: 18.5-24) and thin patients (BMI
- Published
- 2018
- Full Text
- View/download PDF
3. [Treatment of a phytobezoar with PEG 4000]
- Author
-
E, Zrihen, J, Kac, and D, Elias
- Subjects
Bezoars ,Dietary Fiber ,Postoperative Complications ,Gastrectomy ,Stomach Diseases ,Administration, Oral ,Humans ,Vagotomy, Proximal Gastric ,Polyethylene Glycols - Published
- 1992
4. [Adenocarcinoma in heterotopic gastric pancreas]
- Author
-
P, Bedossa, B, Millat, E, Zrihen, and G, Lemaigre
- Subjects
Adult ,Male ,Stomach Neoplasms ,Humans ,Adenocarcinoma ,Choristoma ,Pancreas - Abstract
The development of an adenocarcinoma in heterotopic pancreas of the stomach is uncommon and its diagnosis is difficult. We report the case of a 42 year-old man who was admitted for gastric stasis, related to an antral tumour. He had been treated for Hodgkin's disease by radiation therapy. 16 years ago. Gastrectomy was performed. On light microscopy, the gastric wall was infiltrated by pancreatic ectopic tissue, normal in the submucosa, but dedifferentiated with cytological and architectural criteria of malignancy in the muscular and the serous layers. Malignant transformation of an ectopic pancreas is theoretically possible but is very uncommon. In our case, the role of previous radiation therapy as a promoting factor is discussed.
- Published
- 1991
5. [Gastroduodenal complications of hepatic intra-arterial chemotherapy of hepatic metastases of colorectal origin]
- Author
-
P, Rougier, P, Zimmermann, B, Crespon, M, Ducreux, J, Kac, M, Charbit, E, Zrihen, D, Elias, J, Lumbroso, and P, Lasser
- Subjects
Hepatic Artery ,Liver Neoplasms ,Stomach Diseases ,Humans ,Infusions, Intra-Arterial ,Antineoplastic Agents ,Prospective Studies ,Duodenal Diseases ,Colorectal Neoplasms - Abstract
Fifty-eight patients with colorectal liver metastases were treated by intra-arterial hepatic chemotherapy (IAHC) containing 5 FU (n = 42) or FUDR (n = 16). Twenty-three patients (39.6 p. 100) complained of abdominal pain. In three of these patients, the course was complicated by digestive hemorrhage. Endoscopic explorations and angioscintigraphy were normal in 4, showed oesophagitis in 3, superficial gastritis or duodenitis in 8 (34.7 p. 100) and gastric (2) or duodenal ulceration (6) in 8 (34.7 p. 100). The duodenal ulceration was extensive and considered to be cause of hemorrhage in two cases. Duodenal perforation due to the catheter was discovered in two other cases, one of which was secondary to tumoral extension revealed by forceps biopsy. This patient died 3 months later. Surgical treatment was mandatory in the other case due to digestive hemorrhage but did not prevent death. Angioscintigraphy performed in 15 patients with gastroduodenal inflammation or ulceration was normal in 7 patients, revealed arterial thrombosis in 5 and an extra-hepatic perfusion in the gastroduodenal area in 3 : this was related to a small pyloric artery which was occluded secondarily. IAHC was continued there after. This experience underlines the importance of exploring patients with digestive symptoms during IAHC so that it may be temporarily discontinued while an inadequately positioned infusion catheter may be corrected should gastroduodenal ulceration occur.
- Published
- 1989
6. Colorectal cancer-associated microbiota contributes to oncogenic epigenetic signatures
- Author
-
Sylvie Rabot, Séverine Couffin, Aurelien Amiot, Biba Nebbad, Emma Bergsten, Khashayarsha Khazaie, Philippe J. Sansonetti, Denis Mestivier, Caroline Barau, Florence Canoui-Poitrine, Thierry Pedron, Iradj Sobhani, Nicola de’Angelis, Service de gastro-entérologie [Henri Mondor AP-HP, Créteil], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor, Early detection of Colon Cancer using Molecular Markers and Microbiota (EA 7375) (EC2M3), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Pathogénie microbienne moléculaire, Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Henri Mondor, Plateforme de Ressources Biologiques [Henri Mondor AP-HP, Créteil] (PRB), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Henri Mondor, Service de chirurgie digestive, MICrobiologie de l'ALImentation au Service de la Santé (MICALIS), Institut National de la Recherche Agronomique (INRA)-AgroParisTech, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Mayo Clinic [Rochester], Chaire Microbiologie et Maladies infectieuses, Collège de France (CdF (institution)), French Institut of CancerMinistry of Health - Turkey : PHRC 2011-VatnimadAOM09268French Society of GastroenterologyLigue Nationale Contre le Cancer for fecal test screening Institut National du CAncer (INCA, Cancéropôle Ile de France, Grant for Microbiota and CRC) National Institute of Health and Medical Research (INSERM) under the Institut Thématique Multi-Organisme program (ITMO)., We thank all patients for their participation and physicians who invited them to participate, they are the following gastroenterologists: Drs. E. Zrihen, O. Pecriaux, J. Samama, M. Petit, Ph. Cattan, M. Cavicchi, Ch. Locher, G. Gattineau, M. Parieto, M. Mozer, A. Rosenbaum, Ph. Capelle, D. Levoir, F. Maille, Ph. Lebourgeois, Ph. De Land, E. Chanteloup, M. Simon, F. Mal, and F. Iglicki. We thank also Drs. J. Tran VanHieu and M. L. Auriault for pathology analyses in human and animals, Prof. S. Loric for biochemistry analysis in mice, Prof. T. Simon, A. Touati, J. Tap, V. Jarrousse, A. Bado, and J. P. Fouret for animal experiments and help managing, A. Wolfe for revising the English, S. Peyvandi for assisting with the animal and molecular experiments, E. Guery and L. Segaux for their statistical contributions, C. Vialette for data managing, A. Caidia (Bioinformatics Core Laboratory) for 16S rRNA analysis, and Catherine Philippe for SCFA analyses in mice. We thank all technicians and scientific consultants from Faculté de Médecine site Pitié Salpêtrière (Assistance Publique-Hôpitaux de Paris [APHP]), Unité Mixte de Service (UMS) 29 Omic Platform p3s for technical help on EPIC methylation array study in mice, and all members of clinical monitoring group from the Unité de Recherche Clinique de l’Est Parisien (URC-Est) Hôpital Saint-Antoine, APHP. We thank all the technicians from the Anaxem germ-free animal facility of the Micalis Institute for breeding the germ-free mice and carrying out FMT and gnotobiotic mice care and monitoring. We thank Dr. Abdulmohammad Pezeshki and Ms. Shatha Awaad for assistance with the analysis of inflammation in mouse colons and Katja Brunner for editing the manuscript., Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Collège de France - Chaire Microbiologie et Maladies infectieuses, PEDRON, Thierry, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Henri Mondor [Créteil], and Hôpital Henri Mondor-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- Subjects
Male ,Colorectal cancer ,[SDV]Life Sciences [q-bio] ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Biology ,Epigenesis, Genetic ,Cohort Studies ,Feces ,03 medical and health sciences ,0302 clinical medicine ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,RNA, Ribosomal, 16S ,microbiota ,medicine ,cancer ,Animals ,Germ-Free Life ,Humans ,Epigenetics ,Intestinal Mucosa ,Promoter Regions, Genetic ,030304 developmental biology ,Mice, Inbred C3H ,0303 health sciences ,Multidisciplinary ,colon ,Cancer ,Promoter ,Methylation ,Biological Sciences ,DNA Methylation ,Fecal Microbiota Transplantation ,medicine.disease ,digestive system diseases ,Gastrointestinal Microbiome ,3. Good health ,[SDV] Life Sciences [q-bio] ,Gene Expression Regulation ,030220 oncology & carcinogenesis ,DNA methylation ,Immunology ,biomarker ,Dysbiosis ,Female ,Colorectal Neoplasms ,gene methylation ,Aberrant crypt foci - Abstract
Sporadic colorectal cancer (CRC) is a result of complex interactions between the host and its environment. Environmental stressors act by causing host cell DNA alterations implicated in the onset of cancer. Here we investigate the stressor ability of CRC-associated gut dysbiosis as causal agent of host DNA alterations. The epigenetic nature of these alterations was investigated in humans and in mice. Germ-free mice receiving fecal samples from subjects with normal colonoscopy or from CRC patients were monitored for 7 or 14 wk. Aberrant crypt foci, luminal microbiota, and DNA alterations (colonic exome sequencing and methylation patterns) were monitored following human feces transfer. CRC-associated microbiota induced higher numbers of hypermethylated genes in murine colonic mucosa (vs. healthy controls’ microbiota recipients). Several gene promoters including SFRP1,2,3, PENK, NPY, ALX4, SEPT9, and WIF1 promoters were found hypermethylated in CRC but not in normal tissues or effluents from fecal donors. In a pilot study ( n = 266), the blood methylation levels of 3 genes ( Wif1 , PENK , and NPY ) were shown closely associated with CRC dysbiosis. In a validation study ( n = 1,000), the cumulative methylation index (CMI) of these genes was significantly higher in CRCs than in controls. Further, CMI appeared as an independent risk factor for CRC diagnosis as shown by multivariate analysis that included fecal immunochemical blood test. Consequently, fecal bacterial species in individuals with higher CMI in blood were identified by whole metagenomic analysis. Thus, CRC-related dysbiosis induces methylation of host genes, and corresponding CMIs together with associated bacteria are potential biomarkers for CRC.
- Published
- 2019
- Full Text
- View/download PDF
7. Effect of real-time computer-aided detection of colorectal adenoma in routine colonoscopy (COLO-GENIUS): a single-centre randomised controlled trial.
- Author
-
Karsenti D, Tharsis G, Perrot B, Cattan P, Percie du Sert A, Venezia F, Zrihen E, Gillet A, Lab JP, Tordjman G, and Cavicchi M
- Subjects
- Male, Humans, Female, Artificial Intelligence, Colonoscopy, Computers, Colonic Polyps diagnostic imaging, Colonic Polyps surgery, Colorectal Neoplasms diagnostic imaging, Colorectal Neoplasms epidemiology, Adenoma diagnostic imaging, Adenoma surgery
- Abstract
Background: Artificial intelligence systems have been developed to improve polyp detection. We aimed to evaluate the effect of real-time computer-aided detection (CADe) on the adenoma detection rate (ADR) in routine colonoscopy., Methods: This single-centre randomised controlled trial (COLO-GENIUS) was done at the Digestive Endoscopy Unit, Pôle Digestif Paris-Bercy, Clinique Paris-Bercy, Charenton-le-Pont, France. All consecutive individuals aged 18 years or older who were scheduled for a total colonoscopy and had an American Society of Anesthesiologists score of 1-3 were screened for inclusion. After the caecum was reached and the colonic preparation was appropriate, eligible participants were randomly assigned (1:1; computer-generated random numbers list) to either standard colonoscopy or CADe-assisted colonoscopy (GI Genius 2.0.2; Medtronic). Participants and cytopathologists were masked to study assignment, whereas endoscopists were not. The primary outcome was ADR, which was assessed in the modified intention-to-treat population (all randomly assigned participants except those with misplaced consent forms). Safety was analysed in all included patients. According to statistical calculations, 20 endoscopists from the Clinique Paris-Bercy had to include approximately 2100 participants with 1:1 randomisation. The trial is complete and registered with ClinicalTrials.gov, NCT04440865., Findings: Between May 1, 2021, and May 1, 2022, 2592 participants were assessed for eligibility, of whom 2039 were randomly assigned to standard colonoscopy (n=1026) or CADe-assisted colonoscopy (n=1013). 14 participants in the standard group and ten participants in the CADe group were then excluded due to misplaced consent forms, leaving 2015 participants (979 [48·6%] men and 1036 [51·4%] women) in the modified intention-to-treat analysis. ADR was 33·7% (341 of 1012 colonoscopies) in the standard group and 37·5% (376 of 1003 colonoscopies) in the CADe group (estimated mean absolute difference 4·1 percentage points [95% CI 0·0-8·1]; p=0·051). One bleeding event without deglobulisation occurred in the CADe group after a large (>2 cm) polyp resection and resolved after a haemostasis clip was placed during a second colonoscopy., Interpretation: Our findings support the benefits of CADe, even in a non-academic centre. Systematic use of CADe in routine colonoscopy should be considered., Funding: None., Competing Interests: Declaration of interests DK is a consultant for Olympus and has received financial support for attending meetings from Alfasigma and Fujifilm. FV has recieved honoraria for lectures, presentations, and speaking at events from AbbVie, Takeda, Amgen, and Janssen-Cilag; financial support for attending meetings from AbbVie; and is on the advisory board for Janssen-Cilag and Biogen. MC is a consultant for Janssen-Cilag, AbbVie, and MSD; has received honoraria for lectures, presentations, and speaking at events for MSD France, Amgen, Takeda, Pfizer, Mylan, and Tillots; financial support for attending meetings from Ferring, Takeda, and MSD; is on the advisory board for Janssen-Cilag and AbbVie; and has received equipment and materials from Celtrion and Biosynex. All other authors declare no competing interests., (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
8. Adenoma detection by Endocuff-assisted versus standard colonoscopy in routine practice: a cluster-randomised crossover trial.
- Author
-
Karsenti D, Tharsis G, Perrot B, Cattan P, Tordjman G, Venezia F, Zrihen E, Gillot D, Gillet A, Hagege C, Samama J, Etienney I, Lab JP, Guigui B, Zago J, Benkessou B, Burtin P, and Cavicchi M
- Subjects
- Colonic Polyps diagnosis, Cross-Over Studies, Early Detection of Cancer, Female, Humans, Male, Middle Aged, Prospective Studies, Adenoma diagnosis, Colonic Neoplasms diagnosis, Colonoscopy instrumentation, Rectal Neoplasms diagnostic imaging
- Abstract
Objective: Endocuff Vision (ECV) is the second generation of a device designed to improve polyp detection. The aim of this study was to evaluate its impact on adenoma detection rate (ADR) in routine colonoscopy., Design: This cluster-randomised crossover trial compared Endocuff-assisted (ECV+) with standard (ECV-) colonoscopy. Two teams of 11 endoscopists each with prior ECV experience, balanced in terms of basal ADR, gender and case volume were compared. In randomised fashion, the teams started with ECV+ or ECV- and switched group after inclusion of half of the cases. The main outcome criterion was ADR difference between ECV+ and ECV-. Subgroup analysis was done for physicians with low and high ADR (< or ≥ 25%)., Results: During two periods of 20 and 21 weeks, respectively, the 22 endoscopists included 2058 patients (1032 ECV- vs 1026 ECV+, both groups being comparable). Overall ADR for both groups taken together was higher with ECV (39.2%) than without (29.4%; p<0.001) irrespective of the sequence of use (ECV+ or ECV- first), but mostly in adenomas <1 cm. In the physician subgroup analysis, only high detectors showed a significant ADR increase (from 31% to 41%, p<0.001), while the increase in the low detectors was not significant (from 24% to 30%, p=0.11). ECV had a positive impact in all colonic locations, except for the rectum. No ECV- related complication was reported., Conclusion: We observed a significant ADR difference of approximately 10% by the use of ECV. By subgroup analysis, this increase was significant only in physicians classified as high detectors., Trial Registration Number: ClinicalTrials.gov (NCT03344055)., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2020
- Full Text
- View/download PDF
9. [Value of endorectal ultrasonography in the treatment of rectal tumors].
- Author
-
Zrihen E, Ducreux M, Aziza G, Lasser P, Elias D, Bognel C, Kac J, Lusinchi A, and Rougier P
- Subjects
- Evaluation Studies as Topic, Humans, Lymphatic Metastasis, Neoplasm Recurrence, Local diagnostic imaging, Neoplasm Staging, Patient Selection, Rectal Neoplasms pathology, Rectal Neoplasms therapy, Risk Factors, Sensitivity and Specificity, Ultrasonography, Rectal Neoplasms diagnostic imaging
- Abstract
Objectives: To determine the diagnostic accuracy of endosonography and to appreciate its influence on the therapeutic strategy., Methods: Sixty-two patients referred to the gastroenterology unit between April 1990 and February 1995 for a rectal tumor. Thirty-two patients did not receive any preoperative treatment (group A) and 30 were treated by radiotherapy or chemoradiotherapy before surgery (group B). Transrectal ultrasonography was performed with a Bruel and Kjaer device., Results: Diagnostic accuracy for parietal infiltration was 84% for the entire series, 94% for group A and 73% for group B. Diagnostic accuracy of lymph node invasion was 71% for the entire series, 81% and 60% for groups A and B, respectively. It is highly probable that a histopathologic down-staging due to preoperative treatment explained the results in the group B. Using a pragmatic approach which combined the results for parietal infiltration and for lymph node invasion, transrectal ultrasonography would have correctly selected 20 among the 25 patients who could have been treated by local excision. The use of this same pragmatic approach in patients with high risk of local recurrence enabled correct selection of 26 among the 32 exposed patients., Conclusion: We conclude that transrectal ultrasonography: 1. is a reliable technique for the pretherapeutic staging of rectal cancer, especially for the assessment of parietal infiltration. Progress is needed for the diagnosis of lymph node invasion; 2. selects well the patients who can be treated by local excision; 3. is a reliable technique for the selection of patients who need preoperative treatment.
- Published
- 1996
10. [Rectal lymphoma: endorectal ultrasound aspect].
- Author
-
Zrihen E, Aziza G, Crespon B, and Rougier P
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Combined Modality Therapy, Endoscopy, Humans, Lymphoma, Non-Hodgkin therapy, Male, Mediastinal Neoplasms pathology, Middle Aged, Neoplasms, Second Primary therapy, Radiography, Rectal Neoplasms therapy, Ultrasonography, Lymphoma, Non-Hodgkin diagnostic imaging, Neoplasms, Second Primary diagnostic imaging, Rectal Neoplasms diagnostic imaging
- Published
- 1992
11. [Treatment of a phytobezoar with PEG 4000].
- Author
-
Zrihen E, Kac J, and Elias D
- Subjects
- Administration, Oral, Bezoars drug therapy, Gastrectomy adverse effects, Humans, Polyethylene Glycols administration & dosage, Postoperative Complications, Stomach Diseases etiology, Vagotomy, Proximal Gastric adverse effects, Bezoars etiology, Dietary Fiber adverse effects, Polyethylene Glycols therapeutic use, Stomach Diseases drug therapy
- Published
- 1992
12. [Adenocarcinoma in heterotopic gastric pancreas].
- Author
-
Bedossa P, Millat B, Zrihen E, and Lemaigre G
- Subjects
- Adenocarcinoma etiology, Adenocarcinoma pathology, Adult, Choristoma complications, Humans, Male, Stomach Neoplasms complications, Stomach Neoplasms pathology, Adenocarcinoma diagnosis, Choristoma diagnosis, Pancreas, Stomach Neoplasms diagnosis
- Abstract
The development of an adenocarcinoma in heterotopic pancreas of the stomach is uncommon and its diagnosis is difficult. We report the case of a 42 year-old man who was admitted for gastric stasis, related to an antral tumour. He had been treated for Hodgkin's disease by radiation therapy. 16 years ago. Gastrectomy was performed. On light microscopy, the gastric wall was infiltrated by pancreatic ectopic tissue, normal in the submucosa, but dedifferentiated with cytological and architectural criteria of malignancy in the muscular and the serous layers. Malignant transformation of an ectopic pancreas is theoretically possible but is very uncommon. In our case, the role of previous radiation therapy as a promoting factor is discussed.
- Published
- 1991
13. [Gastroduodenal complications of hepatic intra-arterial chemotherapy of hepatic metastases of colorectal origin].
- Author
-
Rougier P, Zimmermann P, Crespon B, Ducreux M, Kac J, Charbit M, Zrihen E, Elias D, Lumbroso J, and Lasser P
- Subjects
- Antineoplastic Agents administration & dosage, Hepatic Artery, Humans, Liver Neoplasms secondary, Prospective Studies, Antineoplastic Agents adverse effects, Colorectal Neoplasms, Duodenal Diseases chemically induced, Infusions, Intra-Arterial adverse effects, Liver Neoplasms drug therapy, Stomach Diseases chemically induced
- Abstract
Fifty-eight patients with colorectal liver metastases were treated by intra-arterial hepatic chemotherapy (IAHC) containing 5 FU (n = 42) or FUDR (n = 16). Twenty-three patients (39.6 p. 100) complained of abdominal pain. In three of these patients, the course was complicated by digestive hemorrhage. Endoscopic explorations and angioscintigraphy were normal in 4, showed oesophagitis in 3, superficial gastritis or duodenitis in 8 (34.7 p. 100) and gastric (2) or duodenal ulceration (6) in 8 (34.7 p. 100). The duodenal ulceration was extensive and considered to be cause of hemorrhage in two cases. Duodenal perforation due to the catheter was discovered in two other cases, one of which was secondary to tumoral extension revealed by forceps biopsy. This patient died 3 months later. Surgical treatment was mandatory in the other case due to digestive hemorrhage but did not prevent death. Angioscintigraphy performed in 15 patients with gastroduodenal inflammation or ulceration was normal in 7 patients, revealed arterial thrombosis in 5 and an extra-hepatic perfusion in the gastroduodenal area in 3 : this was related to a small pyloric artery which was occluded secondarily. IAHC was continued there after. This experience underlines the importance of exploring patients with digestive symptoms during IAHC so that it may be temporarily discontinued while an inadequately positioned infusion catheter may be corrected should gastroduodenal ulceration occur.
- Published
- 1989
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.